{"id":"W4235951270","doi":"10.3747/co.26.4096","title":"Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Oncology; Lung cancer; Radiation therapy; Internal medicine; Chemotherapy; Stage (stratigraphy); Clinical trial; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008418113,0.0003394847,0.0007114533,0.0001134194,0.00009356423,0.00001372401,0.0001051995,0.0001083541,0.0005462232],"category_scores_gemma":[0.00001569351,0.000241252,0.0002290011,0.0001304643,0.00005484801,0.00008463817,0.00003304797,0.0001532695,0.00005288402],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004103539,"about_ca_system_score_gemma":0.0007323395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009050485,"about_ca_topic_score_gemma":0.0003022082,"domain_scores_codex":[0.9982833,0.00003565581,0.0002792954,0.0007109851,0.0001719561,0.0005188321],"domain_scores_gemma":[0.9987715,0.0002828343,0.0001731431,0.0003893612,0.0001943,0.0001888943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01220593,0.02304488,0.4056616,0.00341154,0.00151447,0.00009183811,0.01088108,0.003513874,0.002418509,0.002316087,0.009242761,0.5256974],"study_design_scores_gemma":[0.0535354,0.02390201,0.008952891,0.00105615,0.0009531335,0.000006575356,0.005044985,0.002189995,0.013697,0.00004395072,0.8900228,0.0005950955],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9228618,0.05660497,0.0003794632,0.001318528,0.002536731,0.004925001,0.0001388967,0.00007772557,0.01115693],"genre_scores_gemma":[0.9527395,0.03277828,0.0007665089,0.000208936,0.0005202419,0.004199655,0.00009503842,0.00006194168,0.008629877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.88078,"threshold_uncertainty_score":0.9997196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04177159213969803,"score_gpt":0.4109122224770908,"score_spread":0.3691406303373927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}